Artelo Biosciences 将来の成長

NasdaqCM:ARTL - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-19	-18	-18	2
12/31/2025	N/A	-11	-10	-10	3
12/31/2024	N/A	-8	-17	-17	3
9/30/2024	N/A	-9	-8	-8	N/A
6/30/2024	N/A	-10	-9	-9	N/A
3/31/2024	N/A	-10	-9	-9	N/A
12/31/2023	N/A	-9	-8	-8	N/A
9/30/2023	N/A	-10	-8	-8	N/A
6/30/2023	N/A	-9	-8	-8	N/A
3/31/2023	N/A	-10	-8	-8	N/A
12/31/2022	N/A	-10	-8	-8	N/A
9/30/2022	N/A	-13	-9	-9	N/A
6/30/2022	N/A	-13	-9	-9	N/A
3/31/2022	N/A	-12	-8	-8	N/A
12/31/2021	N/A	-12	-8	-8	N/A
11/30/2021	N/A	-9	-7	-7	N/A
8/31/2021	N/A	-7	-6	-6	N/A
5/31/2021	N/A	-7	-5	-5	N/A
2/28/2021	N/A	-5	-5	-5	N/A
11/30/2020	N/A	-5	-5	-5	N/A
8/31/2020	N/A	-5	-4	-4	N/A
5/31/2020	N/A	-4	-6	-5	N/A
2/29/2020	N/A	-4	-6	-4	N/A
11/30/2019	N/A	-3	-5	-3	N/A
8/31/2019	N/A	-2	-4	-3	N/A
5/31/2019	N/A	-2	-2	-2	N/A
2/28/2019	N/A	-2	-2	-2	N/A
11/30/2018	N/A	-3	-2	-2	N/A
8/31/2018	N/A	-2	N/A	-2	N/A
5/31/2018	N/A	-2	N/A	-1	N/A
2/28/2018	N/A	-1	N/A	-1	N/A
11/30/2017	N/A	-1	N/A	0	N/A
8/31/2017	N/A	0	N/A	0	N/A
5/31/2017	N/A	0	N/A	0	N/A
2/28/2017	N/A	0	N/A	0	N/A
11/30/2016	N/A	0	N/A	0	N/A
8/31/2016	N/A	0	N/A	0	N/A
5/31/2016	N/A	0	N/A	0	N/A
2/29/2016	N/A	0	N/A	0	N/A
11/30/2015	N/A	0	N/A	0	N/A
8/31/2015	N/A	0	N/A	0	N/A
5/31/2015	N/A	0	N/A	0	N/A
2/28/2015	N/A	0	N/A	0	N/A
11/30/2014	N/A	0	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ARTL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ARTL今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ARTL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ARTL来年は収益がないと予測されています。

高い収益成長: ARTL来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ARTLの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Artelo Biosciences 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 16% to US$35.00

Price target increased to US$57.50

Price target decreased to US$4.08

Recent updates

New minor risk - Share price stability

Artelo Biosciences, Inc., Annual General Meeting, Dec 20, 2024

Artelo Biosciences, Inc. Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program

Insufficient new directors

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12

Artelo Biosciences, Inc. Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Artelo Biosciences, Inc. Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform

New major risk - Revenue and earnings growth

New major risk - Financial position

Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

New major risk - Revenue and earnings growth

Artelo Biosciences Selects for Oral Presentation to Report Positive Research Findings on Art12.11

Artelo Biosciences, Inc., Annual General Meeting, Jun 30, 2023

Price target decreased by 16% to US$35.00

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

High number of new directors

Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Price target increased to US$57.50

Artelo Biosciences, Inc. Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13

Artelo Biosciences, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$4.08

High number of new directors

Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results for Lead Program in Cancer-Related Cachexia

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

Artelo Biosciences, Inc. Anticipates Accelerated Clinical Development for ART27.13

High number of new directors

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

High number of new and inexperienced directors

Independent Director John Beck has left the company

Relief For Cancer Patients In Artelo Bioscience Pipeline

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences, Inc. Appoints Tamara A. Seymour to its Board of Directors

Artelo Biosciences, Inc. Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal

New 90-day high: US$1.28

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia

INO, VXRT, BTU and TTM among premarket gainers

Artelo Biosciences EPS misses by $0.04

New 90-day high: US$1.00

Artelo Biosciences, Inc. Appoints Gregory R. Reyes to the Company’s Board of Directors

Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss

Artelo Biosciences on go with cancer appetite recovery study

New 90-day low: US$0.65

Artelo Biosciences, Inc. has completed a Composite Units Offering in the amount of $6.6 million.

Artelo Biosciences, Inc. Receives Ethics Approval to Commence Its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia

New 90-day low: US$0.71

New 90-day low - US$0.94

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘